We at the Arcady Group were thrilled to support this (another) important and successful evaluation of medication monitors to support the care of self-administering TB patients. Not only were the medication monitors well accepted by both patients and providers, but they were successfully used to inform and enable differentiated care — directing more care and support to those patients that need it most. We were especially grateful to see that China was able to develop this “indigenous” monitoring device based largely on information we at Arcady made available via our global access commitment to the Bill & Melinda Gates Foundation.